Literature DB >> 25740020

Primary cardiac leiomyosarcoma: an analysis of clinical characteristics and outcome patterns.

Ji-Gang Wang1, Li Cui2, Tao Jiang3, Yu-Jun Li1, Zhi-Min Wei4.   

Abstract

BACKGROUND: Primary cardiac leiomyosarcoma is an extremely rare entity. There is no accumulated knowledge about the clinical characteristics and therapeutic strategies for this tumor. This study aimed to systematically review the available literature to investigate the clinicoradiologic and clinicopathologic characteristics, treatment, and outcomes in patients with primary cardiac leiomyosarcoma.
METHODS: We identified 79 instances derived from 72 unique reports and carefully analyzed all clinical presentations, imaging, pathology, treatments, and outcomes.
RESULTS: The mean age at onset was 48 years. A symptom of obstruction was the most frequent complaint at diagnosis. Routine imaging methods such as echocardiography, computed tomography, and magnetic resonance imaging had high sensitivity in diagnosis. The tumor has a poorer life expectancy than its counterparts in other sites. The 5-year overall survival and recurrence-free survival rates were 25.4% and 14.7%, respectively. Overall survival was affected by age, surgery, and adjunctive chemotherapy or radiotherapy.
CONCLUSIONS: Our findings suggest that primary cardiac leiomyosarcomas tend to be biologically more aggressive compared to their counterparts in other sites. However, complete resection and adjunctive chemotherapy or radiotherapy may help to increase the life expectancy.
© The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Chemotherapy; Heart neoplasms; Leiomyosarcoma; Prognosis; Radiotherapy; Survival analysis; adjuvant

Mesh:

Year:  2015        PMID: 25740020     DOI: 10.1177/0218492315574197

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  8 in total

1.  Primary cardiac leiomyosarcoma presenting as haemoptysis in a 22-year-old patient: an unusual presentation of a rare condition.

Authors:  Masroor Hassan; Maria Khattak; Hafez Mohammad Ammar Abdullah; Bushra Nasib
Journal:  BMJ Case Rep       Date:  2017-07-13

2.  Cardiac masses : Experience from a Turkish tertiary center of cardiology.

Authors:  C Gecmen; G G Gecmen; M Kahyaoglu; B Omar; S Izci; A Kalayci; C Y Karabay; S Coban; O Candan; E Yanik; I A Izgi; N O Barisik
Journal:  Herz       Date:  2016-12-01       Impact factor: 1.443

3.  A case report of a primary pericardial leiomyosarcoma: An extremely rare cardiac neoplasm.

Authors:  Achraf Machraa; Hanaa El Ghiati; Zineb Fassi Fehri; Cyrille Mbida; Hafsa Chahdi; Fouad Nya; Younes Moutakillah; Zouhair Lakhal; Najat Mouine; Aatif Benyass
Journal:  Ann Med Surg (Lond)       Date:  2022-04-29

Review 4.  Cardial leiomyosarcoma with multiple lesions involved: a case report.

Authors:  Yan Lv; Xin Pang; Qingfu Zhang; Dalin Jia
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  Management of a primary cardiac leiomyosarcoma in a young woman.

Authors:  Mehmet Akif Önalan; Ahmet Demirkaya; Kemal Behzatoglu; Ersin Erek
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2021-04-26       Impact factor: 0.332

6.  Two years survival of primary cardiac leiomyosarcoma managed by surgical and adjuvant therapy.

Authors:  K Behi; M Ayadi; E Mezni; K Meddeb; A Mokrani; Y Yahyaoui; F Ksontini; H Rais; N Chrait; A Mezlini
Journal:  Clin Sarcoma Res       Date:  2017-03-09

7.  Immunohistochemical Diagnosis of Primary Cardiac Leiomyosarcoma in a Latin American Patient.

Authors:  Ruben Blachman-Braun; Carlos Manuel Aboitiz-Rivera; Alberto Aranda-Fraustro; Adrián Ransom-Rodríguez; Mario Enrique Baltazares-Lipp; Jorge Manuel Catrip-Torres; Jesús Octavio Martínez-Reding
Journal:  Rare Tumors       Date:  2017-03-28

Review 8.  Genetic aberrations and molecular biology of cardiac sarcoma.

Authors:  Milena Urbini; Annalisa Astolfi; Valentina Indio; Margherita Nannini; Carmine Pizzi; Pasquale Paolisso; Giuseppe Tarantino; Maria Abbondanza Pantaleo; Maristella Saponara
Journal:  Ther Adv Med Oncol       Date:  2020-05-18       Impact factor: 8.168

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.